Pyruvate Kinase M2 (PKM2) is a rate-limiting glycolytic enzyme that plays a pivotal role in the Warburg effect, metabolic reprogramming, and transcriptional regulation in cancer cells. As a highly dynamic protein transitioning between an inactive dimer and an active tetramer, PKM2 is a prime target for oncology (inhibitors/activators) and rare metabolic diseases (activators). Developing highly selective small molecules requires robust assay systems to differentiate PKM2 from its closely related isoform PKM1.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PKM2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PKM2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli expressed for native metabolic study. |
View PKM2 Products |
| Gene Delivery | PKM2 Promise-ORF / Lentivirus Full-length ORF for stable cell line development and overexpression assays. |
View PKM2 Products |
| Benchmark Ab | Anti-PKM2 Recombinant Antibody Sequence-derived positive control for Western Blot, IP, and ELISA validation. |
View PKM2 Products |
| Validator | PKM2 siRNA Set For gene knockdown verification in cell-based functional assays. |
View PKM2 Products |
| Related Target A | PKM1 Recombinant Protein Crucial isoform counter-screen target (differing by a single mutually exclusive exon). |
View PKM1 Products |
| Related Target B | LDHA Recombinant Protein Downstream metabolic partner converting pyruvate to lactate in the glycolytic pathway. |
View LDHA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PKM1 vs PKM2 Isoform Selectivity | Sequence-verified recombinant PKM1 and PKM2 proteins available with >95% purity for robust counter-screening panels. |
| Dimer vs Tetramer State Characterization | High-concentration, endotoxin-controlled formulations suitable for oligomerization and biophysical characterization. |
| Lack of Controls | Sequence-defined Biosimilar and Recombinant positive control antibodies included. |
| False Positives in Splicing Modulation | Validated siRNA sets included for target specificity verification in cell-based models. |
Live PKM2/PKM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PKM2 spans two distinct paradigms: activation and inhibition. In rare hematological disorders, such as pyruvate kinase deficiency, small-molecule allosteric activators (e.g., Mitapivat) have successfully achieved regulatory approval. In oncology, the race is focused on disrupting the metabolic flexibility of cancer cells. While early efforts focused on direct enzymatic inhibition (e.g., Shikonin derivatives), the current trend is shifting toward small-molecule activators that force PKM2 into a permanent tetramer state, thereby depriving tumor cells of the glycolytic intermediates required for rapid proliferation. Future R&D is heavily focused on targeting the non-metabolic, nuclear translocation functions of PKM2 which drive gene transcription in resistant solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Agios Pharmaceuticals, Agios/Servier | Pyruvate Kinase Deficiency, Solid Tumors | Enzymatic activation assays (Requires high-purity, sequence-verified PKM2 and PKM1 for selectivity screening) |
| Small Molecule Inhibitors | Preclinical programs | Refractory Glioblastoma, Colorectal Cancer | Oligomeric state transition assays (Requires assay-grade recombinant proteins with low endotoxin) |
| Splicing Modulators (Antisense/Small Mol) | Academic & Biotech Consortia | Metabolic reprogramming in oncology | Isoform expression monitoring (Requires sequence-verified PKM1 and PKM2 control plasmids/lentiviruses) |